Asymmetric dimethylarginine in response to recombinant tissue-type plasminogen activator and erythropoietin in acute stroke

Stroke

Volumn 44, Issue 8, 2013, Pages 2128-2133

  Worthmann, Hans ^a   Martens Lobenhoffer, Jens ^b   Joumaah, Majed ^a   Li, Na ^a,c,d   Lichtinghagen, Ralf ^a   Hecker, Hartmut ^a   Kielstein, Jan T ^a   Ehrenreich, Hannelore ^e   Bode Böger, Stefanie M ^b   Weissenborn, Karin ^a,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^c CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

asymmetric dimethylarginine; clinical trial; erythropoietin; ischemic stroke; rtPA

Indexed keywords

ALTEPLASE; ERYTHROPOIETIN; N(G),N(G) DIMETHYLARGININE; PLACEBO;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTERY OCCLUSION; ARTICLE; BRAIN ISCHEMIA; CLINICAL FEATURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ASYMMETRIC DIMETHYLARGININE; CLINICAL TRIAL; ERYTHROPOIETIN; ISCHEMIC STROKE; RTPA;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ARGININE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84880829916     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.001145     Document Type: Article

References (27)

1. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97:10526-10531.
2. Jerndal M, Forsberg K, Sena ES, Macleod MR, O'Collins VE, Linden T, et al. A systematic review and meta-analysis of erythropoietin in experimental stroke. J Cereb Blood Flow Metab. 2010;30:961-968.
3. Reitmeir R, Kilic E, Kilic U, Bacigaluppi M, ElAli A, Salani G, et al. Post-acute delivery of erythropoietin induces stroke recovery by promoting perilesional tissue remodelling and contralesional pyramidal tract plasticity. Brain. 2011;134(pt 1):84-99.
4. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and benefcial. Mol Med. 2002;8:495-505. (Pubitemid 36337492)
5. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al; EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40:e647-e656.
6. Ehrenreich H. EPO Stroke Studies. www.epo-study.de. Accessed January 22, 2013.
7. Jia L, Chopp M, Zhang L, Lu M, Zhang Z. Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke. Stroke. 2010;41:2071-2076.
8. Zechariah A, ElAli A, Hermann DM. Combination of tissue-plasmino-gen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice. Stroke. 2010;41:1008-1012.
9. Worthmann H, Chen S, Martens-Lobenhoffer J, Li N, Deb M, Tryc AB, et al. High plasma dimethylarginine levels are associated with adverse clinical outcome after stroke. J Atheroscler Thromb. 2011;18:753-761.
10. Scherbakov N, Sandek A, Martens-Lobenhoffer J, Kung T, Turhan G, Liman T, et al. Endothelial dysfunction of the peripheral vascular bed in the acute phase after ischemic stroke. Cerebrovasc Dis. 2012;33:37-46.
11. Chen S, Li N, Deb-Chatterji M, Dong Q, Kielstein JT, Weissenborn K, et al. Asymmetric dimethylarginine as marker and mediator in ischemic stroke. Int J Mol Sci. 2012;13:15983-16004.
12. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, et al. ADMA increases arterial stiffness and decreases cerebral blood fow in humans. Stroke. 2006;37:2024-2029. (Pubitemid 44309898)
13. Sydow K, Münzel T. ADMA and oxidative stress. Atheroscler Suppl. 2003;4:41-51. (Pubitemid 38234494)
14. Chen S, Martens-Lobenhoffer J, Weissenborn K, Kielstein JT, Lichtinghagen R, Deb M, et al. Association of dimethylargi-nines and mediators of infammation after acute ischemic stroke. J Neuroinfammation. 2012;9:251.
15. Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel SC, Täger M, Bode-Böger SM. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol. 2005;16:892-898. (Pubitemid 41710299)
16. Desai A, Zhao Y, Warren JS. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice. Nephrol Dial Transplant. 2008;23:1513-1520. (Pubitemid 351767760)
17. Martens-Lobenhoffer J, Bode-Böger SM. Quantifcation of L-arginine, asymmetric dimethylarginine and symmetric dimethylarginine in human plasma: a step improvement in precision by stable isotope dilution mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;904:140-143.
18. Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation. 2004;109:1813-1818.
19. Jin JS, D'Alecy LG. Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor. J Cardiovasc Pharmacol. 1996;28:439-446. (Pubitemid 26317444)
20. Faraci FM, Brian JE Jr, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol. 1995;269(5 pt 2):H1522-H1527. (Pubitemid 3005958)
21. Dayoub H, Rodionov RN, Lynch C, Cooke JP, Arning E, Bottiglieri T, et al. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. Stroke. 2008;39:180-184.
22. Harston GW, Sutherland BA, Kennedy J, Buchan AM. The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity. J Cereb Blood Flow Metab. 2010;30:1804-1816.
23. Willmot M, Gray L, Gibson C, Murphy S, Bath PM. A systematic review of nitric oxide donors and L-arginine in experimental stroke; effects on infarct size and cerebral blood fow. Nitric Oxide. 2005;12:141-149. (Pubitemid 40432134)
24. Bode-Böger SM, Muke J, Surdacki A, Brabant G, Böger RH, Frölich JC. Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc Med. 2003;8:77-81. (Pubitemid 37168247)
25. Brouns R, Marescau B, Possemiers I, Sheorajpanday R, De Deyn PP. Dimethylarginine levels in cerebrospinal fuid of hyperacute ischemic stroke patients are associated with stroke severity. Neurochem Res. 2009;34:1642-1649.
26. Schulze F, Carter AM, Schwedhelm E, Ajjan R, Maas R, von Holten RA, et al. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis. 2010;208:518-523.
27. Ehrenreich H, Kästner A, Weissenborn K, Streeter J, Sperling S, Wang KK, et al. Circulating damage marker profles support a neuroprotec-tive effect of erythropoietin in ischemic stroke patients. Mol Med. 2011;17:1306-1310.